JAMA : the journal of the American Medical Association, 2011-11-02, Vol.306 (17), p.1874-1883
CONTEXT A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions. OBJECTIVE To describe outcomes of patients 60 years or older after receiving minimally toxic nonmyeloablative allogeneic HCT. DESIGN, SETTING, AND PARTICIPANTS From 1998 to 2008, 372 patients aged 60 to 75 years were enrolled in prospective clinical HCT trials at 18 collaborating institutions using conditioning with low-dose total body irradiation alone or combined with fludarabine, 90 mg/m2, before related (n = 184) or unrelated (n = 188) donor transplants. Postgrafting immunosuppression included mycophenolate mofetil and a calcineurin inhibitor. MAIN OUTCOME MEASURES Overall and progression-free survival were estimated by Kaplan-Meier method. Cumulative incidence estimates were calculated for acute and chronic graft-vs-host disease, toxicities, achievement of full donor chimerism, complete remission, relapse, and nonrelapse mortality. Hazard ratios (HRs) were estimated from Cox regression models. RESULTS Overall, 5-year cumulative incidences of nonrelapse mortality and relapse were 27% (95% CI, 22%-32%) and 41% (95% CI, 36%-46%), respectively, leading to 5-year overall and progression-free survival of 35% (95% CI, 30%-40%) and 32% (95% CI, 27%-37%), respectively. These outcomes were not statistically significantly different when stratified by age groups. Furthermore, increasing age was not associated with increases in acute or chronic graft-vs-host disease or organ toxicities. In multivariate models, HCT-specific comorbidity index scores of 1 to 2 (HR, 1.58 [95% CI, 1.08-2.31]) and 3 or greater (HR, 1.97 [95% CI, 1.38-2.80]) were associated with worse survival compared with an HCT-specific comorbidity index score of 0 (P = .003 overall). Similarly, standard relapse risk (HR, 1.67 [95% CI, 1.10-2.54]) and high relapse risk (HR, 2.22 [95% CI, 1.43-3.43]) were associated with worse survival compared with low relapse risk (P 〈 .001 overall). CONCLUSION Among patients aged 60 to 75 years treated with nonmyeloablative allogeneic HCT, 5-year overall and progression-free survivals were 35% and 32%, respectively.
Biological and medical sciences ; General aspects ; Medical sciences ; Hematologic Neoplasms - therapy ; Whole-Body Irradiation ; Prospective Studies ; Age Factors ; Follow-Up Studies ; Humans ; Middle Aged ; Hematopoietic Stem Cell Transplantation ; Male ; Treatment Outcome ; Clinical Trials as Topic ; Vidarabine - analogs & derivatives ; Antineoplastic Agents - administration & dosage ; Radiation Dosage ; Disease Progression ; Transplantation, Homologous ; Survival Analysis ; Female ; Aged ; Vidarabine - administration & dosage ; Transplantation Conditioning ; comparative outcomes research ; comorbidities ; hematopoietic cell transplantation ; withdrawal of immunosuppression ; Marrow transplantation ; survival ; infections ; mortality ; toxicities ; performance status ; age ; graft-versus-host disease
American Medical Association Journals Backfile (through 1997)
Permalink to record
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24711918$$DView record in Pascal Francis